LMO2 and diffuse large B-cell lymphoma: This may reflect that LMO2 expression is a passenger effect of pre-existing expression in GC cells or it may be a consequence of there being different LMO2-binding partners in DLBCL, where it has been shown to bind to ELK1 (ETS-like gene 1), NFATc1 (nuclear factor of activated T cells 1) and LEF1 (lymphoid enhancer-binding factor 1) [116].